Oncotelic Therapeutics (OTLC) Form 3 MATEON THERAPEUTICS / ANTHONY E MAIDA III ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

MAIDA ANTHONY E III

(Last) (First) (Middle)

C/O MATEON THERAPEUTICS, INC.

29397 AGOURA RD., SUITE 107

(Street)

AGOURA HILLS CA 91301

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
05/11/2020

3. Issuer Name and Ticker or Trading Symbol
MATEON THERAPEUTICS INC [ MATN ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	198,668(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series A Convertible Preferred Stock	(2)	(2)	Common Stock	938,646	(3)	D

Explanation of Responses:

1. Reflects securities of the Issuer acquired by the reporting person pursuant to the Agreement and Plan of Merger, effective April 22, 2019, by and among the Issuer, Oncotelic Acquisition Corporation and Oncotelic, Inc.

2. The Series A Convertible Preferred Stock is automatically convertible in the event of a recapitalization and upon approval by stockholders.

3. Each share of Series A Convertible Preferred Stock is convertible into 1,000 shares of Common Stock.

	/s/ Anthony Maida, III	05/21/2020
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.